Xiaomi Shares Jump on Europe EV Expansion Plan 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Add as a preferred source on Google
HOUSTON, March 06, 2018 -- Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that the Company will host a conference call and live webcast on Tuesday, March 13, 2018 at 5:00 p.m. Eastern to report its fourth quarter and full year 2017 financial results and provide a corporate update.
To access the call, participants should dial 877-407-3103 (U.S. domestic) and 201-493-6791 (international) at least 10 minutes prior to the start of the call. The event will be webcast live and can also be accessed in the Events & Presentations section of bellicum.com. An archived version of the webcast will be available for replay in the Investors & Media section of the Bellicum website for at least two weeks following the call.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.
Investors:
Bellicum Pharmaceuticals, Inc.
Alan Musso, CFO
832-384-1116
[email protected]
Media:
BMC Communications
Brad Miles
646-513-3125
[email protected]
Source: Bellicum Pharmaceuticals
